
Splitomicin
CAS No. 5690-03-9
Splitomicin( Splitomicin )
Catalog No. M17730 CAS No. 5690-03-9
Splitomicin (IC50 of 60 μM), a specific inhibitor of NAD(+)-dependent histone deacetylase Sir2p, displays a high activity in a cell-based assay.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 37 | In Stock |
![]() ![]() |
10MG | 51 | In Stock |
![]() ![]() |
25MG | 105 | In Stock |
![]() ![]() |
50MG | 164 | In Stock |
![]() ![]() |
100MG | 309 | In Stock |
![]() ![]() |
200MG | Get Quote | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameSplitomicin
-
NoteResearch use only, not for human use.
-
Brief DescriptionSplitomicin (IC50 of 60 μM), a specific inhibitor of NAD(+)-dependent histone deacetylase Sir2p, displays a high activity in a cell-based assay.
-
DescriptionSplitomicin is a cell-permeable lactone derived from naphthol and known to be a potent selective inhibitor of Sir2 (silent information regulator 2) and HDAC. Splitomicin inhibits the NAD+-dependent deacetylase activity of Sir2 in vitro. It increases the levels of cyclic AMP by inhibiting the activity of cyclic AMP phosphodiesterase, interferes with mobilization of intracellular Ca+2 and ATP release.
-
In VitroCell Proliferation Assay Cell Line:Human breast cancer MCF-7 and lung cancer H1299 cells Concentration:10, 33, 100, and 333 μM Incubation Time:24 hours Result:Inhibited colony formation in a dose-dependent manner.
-
In VivoAnimal Model:C57BL/6 mice aged 12-14 weeks weighing on average 27 g Dosage:80 mg/kg Administration:Intraperitoneal injection every 24 h for 5 days Result:Increased TF activity in mouse carotid artery as compared with the controls.
-
SynonymsSplitomicin
-
PathwayPI3K/Akt/mTOR signaling
-
TargetPI3K
-
RecptorSIRT2p
-
Research AreaCardiovascular Disease
-
Indication——
Chemical Information
-
CAS Number5690-03-9
-
Formula Weight198.22
-
Molecular FormulaC13H10O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (504.49 mM)
-
SMILESO=C1CCc2c3ccccc3ccc2O1
-
Chemical Name1H-benzo[f]chromen-3(2H)-one
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Bedalov A, et al. Proc Natl Acad Sci U S A. 2001, 98(26), 15113-15118.
molnova catalog



related products
-
ST-162
ST-162 is a potent, bifunctional MAPK/PI3K antagonist with IC50 of 191 nM and 398 nM for PI3Kα and MEK1, respectively.
-
mTOR inhibitor 9d
mTOR inhibitor 9d is a dual inhibitor of the protein kinases mTOR and PI3K with an mTOR IC50 value of 0.31 nm, and can be used for the treatment of leukemia, skin cancer, breast cancer, lung cancer and colon cancer.
-
SRX3207
SRX3207 is an inhibitor of Syk and PI3K and relieves tumor immunosuppression.